BioWorld Science: The Daily Drug R&D News Source

Novel antifungal compounds are more potent and less toxic – and will be lower cost
Scientists in the U.K. have used genome mining to identify bacterial species capable of producing novel polyene antifungal compounds that are both more effective and have a more benign side effect profile than approved polyenes such as amphotericin and nystatin.

Liver-targeted ASO tackles early MASLD
Researchers from Yunnan University, Sicagene Bioscience Co. Ltd. and collaborators reported the preclinical efficacy of GS-10c, a GalNAc-conjugated antisense oligonucleotide (ASO) developed to silence serine/threonine kinase 25 (STK25), a lipid droplet-associated kinase implicated in the development of metabolic dysfunction-associated steatotic liver disease (MASLD).

Novel antifungal compounds are more potent and less toxic – and will be lower cost
Scientists in the U.K. have used genome mining to identify bacterial species capable of producing novel polyene antifungal compounds that are both more effective and have a more benign side effect profile than approved polyenes such as amphotericin and nystatin.
Liver-targeted ASO tackles early MASLD
Researchers from Yunnan University, Sicagene Bioscience Co. Ltd. and collaborators reported the preclinical efficacy of GS-10c, a GalNAc-conjugated antisense oligonucleotide (ASO) developed to silence serine/threonine kinase 25 (STK25), a lipid droplet-associated kinase implicated in the development of metabolic dysfunction-associated steatotic liver disease (MASLD).
Create Medicines’ CRT-402 cleared to enter clinic in Australia
Create Medicines Inc. has received Human Research Ethics Committee (HREC) approval in Australia to initiate a first-in-human study of CRT-402, the company’s lead in vivo CAR T candidate for the treatment of autoimmune diseases.
Olix’s OLX-501A reduces visceral fat in obese NHPs
Olix Pharmaceuticals Inc. has released preclinical data from a head-to-head study in obese nonhuman primates (NHPs) showing that OLX-501A, its ALK7-targeting obesity program, achieved greater visceral fat reduction relative to a globally developed comparator compound.
Sitala Bio identifies new complement factor B inhibitors
Sitala Bio Ltd. has divulged complement factor B (CFB) inhibitors reported to be useful for the treatment of cancer, autoimmune and metabolic disease, eye, dermatological, respiratory, cardiovascular and renal disorders, among others.
Taisho licenses Japanese rights to Kaigene’s KG-006
Kaigene Inc. has entered into a licensing agreement with Taisho Pharmaceutical Co. Ltd. for the exclusive development and commercialization of Kaigene’s next-generation human neonatal Fc receptor (FcRn) inhibitor, KG-006, in Japan.

Today's news in brief

BioWorld

BioWorld Asia

BioWorld Science

BioWorld Premium